Effects of vitamin E on cholesterol levels of hypercholesterolemic patients receiving statins

American Journal of Health-System Pharmacy

Volumn 64, Issue 21, 2007, Pages 2257-2266

  Leonard, Scott W ^a   Joss, Jacqueline D ^b   Mustacich, Debbie J ^a   Blatt, David H ^a   Young, Sook Lee ^a   Traber, Maret G ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b Good Samaritan Regional Medical Center   (United States)

Author keywords

Antilipemic agents; Blood levels; Drug interactions; Excretion; Hypercholesterolemia; Lovastatin; Metabolism; Pharmacokinetics; Simvastatin; Vitamin E; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; CYTOCHROME P450; DRUG METABOLITE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 36048998833     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070041     Document Type: Article

References (50)

1. Food and Nutrition Board. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academy Press; 2000:181-283.
2. Ascherio A, Weisskopf MG, O'Reilly EJ et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol. 2005; 57:104-10.
3. Fang JC, Kinlay S, Beltrame J et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002; 359:1108-13.
4. Zandi PP, Anthony JC, Khachaturian AS et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004; 61:82-8.
5. Wright MV, Lawson KA, Weinstein SJ et al. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr. 2006; 84:1200-7.
6. Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294:56-65.
7. Huang HY, Caballero B, Chang S et al. The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a National Institutes of Health state-of-the-science conference. Ann Intern Med. 2006; 145:372-85.
8. Bjelakovic G, Nikalova D, Gluud LL et al. Mortality in randomized trials of antioxidant supplements for primary or secondary prevention: systematic review and meta-analysis. JAMA. 2007; 297:842-57.
9. Hathcock JN, Azzi A, Blumberg J et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr. 2005; 81:736-45.
10. Cheung MC, Zhao XQ, Chait A et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol. 2001; 21:1320-6.
11. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001; 345:1583-92.
12. Traber MG. Vitamin E, nuclear receptors and xenobiotic metabolism. Arch Biochem Biophys. 2004; 423:6-11.
13. Traber MG, Siddens LK, Leonard SW et al. α-Tocopherol modulates Cyp3a expression, increases γ-CEHC production and limits tissue γ-tocopherol accumulation in mice fed high γ-tocopherol diets. Free Radic Biol Med. 2005; 38:773-85.
14. Mustacich DJ, Leonard SW, Devereaux MW et al. γ-Tocopherol regulation of hepatic cytochrome P450s and ABC transporters. Free Radic Biol Med. 2006; 41:1069-78.
15. Brigelius-Flohé R, Traber MG. Vitamin E: function and metabolism. FASEB J. 1999; 13:1145-55.
16. Kiyose C, Saito H, Kaneko K et al. Alpha-tocopherol affects the urinary and biliary excretion of 2,7,8-trimethyl-2 (2′-carboxyethyl)-6- hydroxychroman, gamma-tocopherol metabolite, in rats. Lipids. 2001; 36:467-72.
17. Sontag TJ, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism: novel mechanism of regulation of vitamin E status. J Biol Chem. 2002; 277:25290-6.
18. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002; 41:343-70.
19. Wallstrom P, Wirfalt E, Lahmann P et al. Serum concentrations of beta-carotene and alpha-tocopherol are associated with diet, smoking, and general and central adiposity. Am J Clin Nutr. 2001; 73:777-85.
20. Guengerich FP. Cytochromes P450, drugs, and diseases. Mol Interv. 2003; 3:194-204.
21. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002; 23:687-702.
22. Weis OF, Luus HG, Muller FO. Minimization - a method of obtaining comparable groups in clinical trials. S Afr Med J. 1984; 66:180-2.
23. Podda M, Weber C, Traber MG et al. Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinols and ubiquinones. J Lipid Res. 1996; 37:893-901.
24. Allain CC, Poon LS, Chan CS et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20:470-5.
25. Sugiuchi H, Uji Y, Okabe H et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem. 1995; 41:717-23.
26. McGowan MW, Artiss JD, Strandbergh DR et al. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983; 29:538-42.
27. Tietz NW, ed. Clinical guide to laboratory tests. Philadelphia: W. B. Saunders; 2000.
28. Leonard SW, Gumpricht E, Devereaux MW et al. Quantitation of rat liver vitamin E metabolites by LC-MS during high-dose vitamin E administration. J Lipid Res. 2005; 46:1068-75.
29. Lykkesfeldt J, Loft S, Poulsen HE. Simultaneous determination of urinary free cortisol and 6 beta-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B Biomed Appl. 1994; 660:23-9.
30. Ohno M, Yamaguchi I, Saiki K et al. Specific determination of urinary 6beta-hydroxycortisol and cortisol by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Appl. 2000; 746:95-101.
31. Hervey GR. Determination of creatinine by the Jaffe reaction. Nature. 1953; 171:1125.
32. Handelman GJ, Machlin LJ, Fitch K et al. Oral α-tocopherol supplements decrease plasma α-tocopherol levels in humans. J Nutr. 1985; 115:807-13.
33. Bruno RS, Ramakrishnan R, Montine TJ et al. α-tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. Am J Clin Nutr. 2005; 81:95-103.
34. Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol. 2003; 59:713-33.
35. Shikany JM, Patterson RE, Agurs-Collins T et al. Antioxidant supplement use in Women's Health Initiative participants. Prev Med. 2003; 36:379-87.
36. Ford ES, Ajani UA, Mokdad AH. Brief communication: the prevalence of high intake of vitamin E from the use of supplements among U.S. adults. Ann Intern Med. 2005; 143:116-20.
37. Devaraj S, Adams-Huet B, Fuller CJ et al. Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation. Arterioscler Thromb Vasc Biol. 1997; 17:2273-9.
38. Schultz M, Leist M, Petrzika M et al. Novel urinary metabolite of alpha-tocopherol, 2,5,7,8-tetramethyl-2(2′-carboxyethyl)-6-hydroxychroman, as an indicator of an adequate vitamin E supply? Am J Clin Nutr. 1995; 62(suppl):1527S-34S.
39. Singh U, Otvos J, Dasgupta A et al. High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Clin Chem. 2007; 53:1-4.
40. Hermann WJ Jr, Ward K, Faucett J. The effect of tocopherol on high-density lipoprotein cholesterol. A clinical observation. Am J Clin Pathol. 1979; 72:848-52.
41. Hatam LJ, Kayden HJ. The failure of α-tocopherol supplementation to alter the distribution of lipoprotein cholesterol in normal and hyperlipoproteinemic persons. Am J Clin Pathol. 1981; 76:122-4.
42. Salonen RM, Nyyssonen K, Kaikkonen J et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation. 2003; 107:947-53.
43. Aldred S, Sozzi T, Mudway I et al. Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects. Proteomics. 2006; 6:1695-703.
44. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006; 84:276-94.
45. Klerkx AH, El Harchaoui K, van der Steeg WA et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol. 2006; 26:706-15.
46. Schaefer EJ, Asztalos BF. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol. 2006; 17:394-8.
47. Napoli C, Leccese M, Palumbo G et al. Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron Artery Dis. 1998; 9:257-64.
48. Liu XQ, Buchanan W, Matthews AJ et al. Lack of effect of vitamin E on cholesteryl ester transfer and lipoprotein composition in cholesterol-fed rabbits. Comp Blechern Physiol B Biochem Mol Biol. 1997; 117:553-9.
49. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79:8-15.
50. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999; 341:410-8.